- Home
- PSTL vs ALT Comparison
PSTL vs ALT Comparison
Compare PSTL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- ALT
- Stock Information
- Founded
- PSTL 2018
- ALT 1997
- Country
- PSTL United States
- ALT United States
- Employees
- PSTL N/A
- ALT N/A
- Industry
- PSTL Real Estate Investment Trusts
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- ALT Health Care
- Exchange
- PSTL Nasdaq
- ALT Nasdaq
- Market Cap
- PSTL 329.8M
- ALT 292.0M
- IPO Year
- PSTL 2019
- ALT N/A
- Fundamental
- Price
- PSTL $15.84
- ALT $3.83
- Analyst Decision
- PSTL Strong Buy
- ALT Strong Buy
- Analyst Count
- PSTL 1
- ALT 6
- Target Price
- PSTL $17.75
- ALT $17.40
- AVG Volume (30 Days)
- PSTL 149.9K
- ALT 3.0M
- Earning Date
- PSTL 08-04-2025
- ALT 08-12-2025
- Dividend Yield
- PSTL 6.12%
- ALT N/A
- EPS Growth
- PSTL 344.13
- ALT N/A
- EPS
- PSTL 0.39
- ALT N/A
- Revenue
- PSTL $86,535,000.00
- ALT $20,000.00
- Revenue This Year
- PSTL $22.00
- ALT N/A
- Revenue Next Year
- PSTL $9.76
- ALT $761,880.20
- P/E Ratio
- PSTL $40.92
- ALT N/A
- Revenue Growth
- PSTL 26.43
- ALT N/A
- 52 Week Low
- PSTL $12.26
- ALT $2.90
- 52 Week High
- PSTL $15.84
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- PSTL 70.89
- ALT 51.79
- Support Level
- PSTL $15.31
- ALT $3.35
- Resistance Level
- PSTL $15.55
- ALT $3.66
- Average True Range (ATR)
- PSTL 0.24
- ALT 0.19
- MACD
- PSTL 0.11
- ALT 0.07
- Stochastic Oscillator
- PSTL 100.00
- ALT 86.18
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.